News

A large California-based study has shown that patients with heart failure who start taking statins, compared with those who don't, will live longer and have a lower hospitalization risk regardless of cholesterol levels, presence or absence of coronary disease, and other CV drug therapies, “Heartwire” reported this week.

Home November 01, 2006
Home
News

While general endotracheal anesthesia (GETA) is the most common type of anesthesia used in infrainguinal bypasses, a study published in the November issue of the Journal of Vascular Surgery reveals that it may not be the best strategy.

Home November 01, 2006
Home
News

The Certification Commission for Healthcare Information Technology is inviting organizations to submit their ambulatory ...

Home November 01, 2006
Home
News

Results from the Danish SORT-OUT II study, the largest randomized trial to date comparing Taxus and Cypher drug-eluting ...

Home November 01, 2006
Home
News

British researchers have concluded that counseling and education aimed at preventing coronary heart disease have no impact on mortality and little effect in terms of clinical events, reports “heartwire.” Dr Shah Ebrahim (London School of Tropical Medicine, UK) and colleagues report their findings in the Oct. 18, 2006 Cochrane Database of Systematic Reviews.

Home October 30, 2006
Home
News

TeraRecon Inc. and Commissure, Inc. have announced a partnership to integrate and deliver seamless workflow ...

Home October 30, 2006
Home
News

A subset analysis of diabetic patients in the SPIRIT II Clinical trial of the XIENCE V Everolimus Eluting Stent System ...

Home October 30, 2006
Home
News

Agfa HealthCare has signed a multi-million dollar deal with Thomas Memorial Hospital in South Charleston, WV and will ...

Home October 30, 2006
Home
News

The FDA has granted approval to Cook Inc. for its new 36mm Zenith FLEX AAA Endovascular Graft for the treatment of ...

Home October 30, 2006
Home
News

Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the safety and performance of a fully bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease in humans, were presented during the 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

Home October 25, 2006
Home
News

Cardium Therapeutics and its subsidiary InnerCool Therapies reported on preclinical data demonstrating a new and ...

Home October 25, 2006
Home
News

A stent designed to dissolve after it completes its task of propping open narrowed heart arteries is being tested by scientists. The first human experiment with the dissolving stent is being conducted with 26 patients at hospitals in New Zealand and Europe, the Associated Press reported. The study is designed to test whether the stent is safe enough to be used in larger studies.

Home October 24, 2006
Home
News

ev3 Inc. has announced a worldwide fracture-free guarantee in support of its new EverFlex family of stents. In the event ...

Home October 24, 2006
Home
News

GlaxoSmithKline and Flamel Technologies announced FDA approval of once-a-day Coreg CR (carvedilol phosphate) extended ...

Home October 24, 2006
Home
News

Boston Scientific Corporation announced that an independent meta-analysis of more than 3,500 patients from five clinical ...

Home October 24, 2006
Home
Subscribe Now